Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

11.78
+0.63005.65%
Post-market: 11.910.1255+1.07%19:30 EDT
Volume:1.72M
Turnover:20.02M
Market Cap:1.91B
PE:534.53
High:11.79
Open:11.18
Low:11.14
Close:11.15
52wk High:26.54
52wk Low:10.21
Shares:162.00M
Float Shares:70.89M
Volume Ratio:1.47
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0220
EPS(LYR):0.0444
ROE:1.46%
ROA:0.65%
PB:7.91
PE(LYR):265.34

Loading ...

Vertex Pharmaceuticals Price Target Raised to $615.00/Share from $585.00 by UBS

Dow Jones
·
Sep 29

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vertex Minerals Sets October General Meeting for Shareholders

TIPRANKS
·
Sep 25

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 25

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

TIPRANKS
·
Sep 23

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Dow Jones
·
Sep 23

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

TIPRANKS
·
Sep 22

Maze jumps 25% to $27.99 after Vertex kidney disease data

TIPRANKS
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

TIPRANKS
·
Sep 22

Correction to Vertex Material Listing Article on Sept. 17

Dow Jones
·
Sep 21

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 19

Vertex wins approval for 24/7 underground operations at Reward Gold Mine

TIPRANKS
·
Sep 18

Malaysia's Vertex Material Sets Sights on 2027 U.S. Listing

Dow Jones
·
Sep 17

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)

TIPRANKS
·
Sep 16